Piramal Pharma

Piramal Pharma

200.65
+1.67
(0.84%)
Market Cap
26,671.36 Cr
EPS
0.69
PE Ratio
306.15
Dividend Yield
0.07 %
Industry
Healthcare
52 Week High
307.90
52 Week Low
181.73
PB Ratio
3.25
Debt to Equity
0.60
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from9 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,593.60
#1 3,82,358.02
33.10
#1 54,729.00
9.71
#1 10,980
-19.84
39.45
6,009.00
1,59,520.07
70.63
9,712.00
18.67
2,191
26.74
43.85
1,553.40
1,25,469.33
23.63
28,409.50
7.12
5,291
9.88
57.67
3,579.10
1,21,133.01
60.27
11,539.40
6.99
1,911
19.91
51.53
1,268.10
1,05,831.96
#1 18.41
33,741.20
16.73
5,725
1.26
48.40
2,550.60
1,05,270.59
56.03
12,744.20
#1 20.90
2,007
-18.14
55.83
1,013.85
1,02,017.03
21.84
23,511.00
18.55
4,615
2.60
60.44
1,943.90
88,777.03
23.95
22,909.50
13.74
3,306
#1 51.64
50.97
31,150.00
66,191.58
47.11
6,684.70
9.64
1,414
11.55
45.41
5,333.50
63,769.99
27.89
13,458.30
3.70
2,216
21.39
57.64
Forecast
Actual
Growth Rate
Revenue Growth
11.25 %
Net Income Growth
411.80 %
Cash Flow Change
-11.17 %
ROE
386.96 %
ROCE
22.30 %
EBITDA Margin (Avg.)
3.53 %

Quarterly Financial Results

Quarterly Financials
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
1,345
1,612
1,709
2,229
1,574
1,777
1,814
2,196
1,802
1,980
2,034
2,591
1,993
2,320
2,233
2,812
2,031
Expenses
1,197
1,381
1,314
1,733
1,465
1,554
1,629
1,812
1,617
1,646
1,723
2,053
1,747
1,900
1,867
2,193
1,827
EBITDA
148
231
395
495
109
223
185
384
185
334
312
538
246
420
367
619
204
Operating Profit %
9 %
12 %
15 %
19 %
1 %
10 %
5 %
16 %
8 %
14 %
12 %
20 %
10 %
15 %
15 %
20 %
6 %
Depreciation
136
138
147
165
162
166
164
184
174
185
186
196
185
192
197
243
197
Interest
42
49
50
57
62
83
95
104
119
110
106
114
107
108
103
104
86
Profit Before Tax
-30
44
198
273
-115
-26
-74
95
-107
40
19
228
-45
120
67
273
-79
Tax
-2
7
35
69
-6
11
17
45
-9
35
9
126
44
98
63
119
3
Net Profit
-28
37
163
204
-109
-37
-90
50
-99
5
10
101
-89
23
4
154
-82
EPS in ₹
0.00
0.31
1.38
1.72
-0.92
-0.31
-0.76
0.42
-0.83
0.04
0.08
0.77
-0.67
0.17
0.03
1.16
-0.62

Balance Sheet

Balance Sheet
2021
2022
2023
2024
2025
Total Assets
10,900
12,797
14,523
15,312
15,678
Fixed Assets
6,106
6,879
7,469
7,990
8,133
Current Assets
3,649
4,067
4,836
5,465
5,797
Capital Work in Progress
627
1,172
1,419
1,116
977
Investments
123
267
639
385
291
Other Assets
4,045
4,478
4,996
5,821
6,277
Total Liabilities
10,900
12,797
14,523
15,312
15,678
Current Liabilities
2,490
3,033
3,843
4,369
3,766
Non Current Liabilities
2,805
3,067
3,906
3,031
3,786
Total Equity
5,605
6,697
6,774
7,911
8,126
Reserve & Surplus
4,610
5,511
5,580
6,588
6,801
Share Capital
995
1,186
1,193
1,323
1,324

Cash Flow

Cash Flow
2021
2022
2023
2024
2025
Net Cash Flow
110
-177
-32
166
-37
Investing Activities
-4,464
-1,737
-1,334
-416
-488
Operating Activities
598
766
484
1,005
892
Financing Activities
3,977
794
818
-422
-441

Share Holding

% Holding
Sept 2022
Oct 2022
Dec 2022
Mar 2023
Jun 2023
Aug 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
34.79 %
0.00 %
34.79 %
34.79 %
34.79 %
35.02 %
35.02 %
35.02 %
35.02 %
34.95 %
34.95 %
34.95 %
34.95 %
34.86 %
FIIs
20.00 %
0.00 %
20.00 %
20.00 %
20.00 %
18.04 %
32.37 %
32.51 %
30.59 %
31.42 %
31.73 %
31.68 %
31.49 %
30.86 %
DIIs
4.86 %
0.00 %
5.28 %
4.99 %
5.49 %
7.83 %
8.02 %
9.68 %
12.12 %
12.95 %
13.81 %
14.10 %
14.78 %
14.26 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.42 %
0.00 %
11.80 %
13.94 %
16.77 %
16.81 %
16.95 %
15.57 %
15.13 %
13.94 %
13.29 %
13.29 %
13.11 %
14.07 %
Others
32.92 %
100.00 %
28.14 %
26.29 %
22.95 %
22.30 %
7.64 %
7.22 %
7.14 %
6.74 %
6.22 %
5.98 %
5.66 %
5.95 %
No of Share Holders
1,79,957
1,79,948
2,29,960
2,41,359
2,77,270
2,95,773
2,97,225
2,92,312
2,97,996
3,06,398
3,59,751
4,18,442
4,32,843
4,58,430

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.56 0.00 0.11 0.14
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.84 0.00 0.05 0.07

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
02 Aug 2023 RIGHTS Rights
5:46
02 Aug 2023 101.95 103.86
12 Jul 2024 DIVIDEND Dividend
₹ 0.11 /share
12 Jul 2024 148.05 151.60
26 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
26 Jul 2024 157.10 166.30
23 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Oct 2024 221.30 215.15
28 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jan 2025 221.25 224.00
14 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 May 2025 214.95 214.90
16 Jul 2025 DIVIDEND Dividend
₹ 0.14 /share
16 Jul 2025 214.90 216.22
28 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jul 2025 216.88 202.23
30 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Jul 2025 199.95 205.61

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Sustainability Report - FY2024-25Aug 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 21, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 20, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 31, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 30, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMJul 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 29, 2025
Unaudited Financial Results (Standalone & Consolidated) For The Quarter Ended 30Th June 2025Jul 28, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 28, 2025
Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited Held On 28Th July 2025Jul 28, 2025
Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - Grant Of Stock OptionsJul 28, 2025
Announcement under Regulation 30 (LODR)-RestructuringJul 22, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJul 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 18, 2025
Board Meeting Intimation for Intimation As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)Jul 18, 2025
Announcement Under Regulation 30 (LODR) - ESG RatingJul 10, 2025
Company Update On LitigationJul 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 02, 2025
Notice Of The 5Th Annual General Meeting (AGM) And Annual Report For The Financial Year 2024-25Jul 02, 2025
Reg. 34 (1) Annual Report.Jul 02, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 26, 2025
Corporate Action-Board to consider DividendJun 13, 2025
Intimation Of Record Date For Payment Of Final DividendJun 13, 2025
Intimation Of 5Th Annual General Meeting To Be Held On Wednesday July 30 2025Jun 13, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations)Jun 13, 2025
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sJun 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 02, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 26, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 14, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMay 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 14, 2025
Audited Financial Results (Standalone & Consolidated) For The Quarter And Financial Year Ended 31St March 2025May 14, 2025
Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited (Company) Held On 14Th May 2025May 14, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) - Capacity Expansion Of Lexington And Riverview SitesMay 12, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) -Successful Closure Of US FDA Inspection At Piramal PharmaS Manufacturing Facility Located At TurbheMay 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 29, 2025
Board Meeting Intimation for Board Meeting Intimation As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Apr 29, 2025

Technical Indicators

RSI(14)
Neutral
57.91
ATR(14)
Less Volatile
5.67
STOCH(9,6)
Neutral
55.70
STOCH RSI(14)
Overbought
94.74
MACD(12,26)
Bullish
1.62
ADX(14)
Strong Trend
26.12
UO(9)
Bearish
52.47
ROC(12)
Uptrend And Accelerating
3.32
WillR(14)
Overbought
-13.26

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
HDFC Flexi Cap Direct Plan-Growth
0.00%
-89000000
-2.17%
-2.24%
HDFC Focused Fund Direct-Growth
0.00%
-25000000
-2.30%
-2.44%
Canara Robeco Small Cap Fund Direct - Growth
0.00%
-6712333
-1.02%
-1.04%
Bandhan Small Cap Fund Direct-Growth
0.00%
-5822899
-0.82%
-0.82%
Kotak Arbitrage Fund Direct-Growth
0.00%
-5540000
-0.15%
-0.07%
Canara Robeco Equity Hybrid Fund Direct-Growth
0.00%
-3150000
-0.56%
-0.57%
Canara Robeco ELSS Tax Saver Direct- Growth
0.00%
-2900000
-0.64%
-0.65%
Franklin India Opportunities Direct Fund-Growth
0.00%
-2555974
-0.68%
-0.72%
HDFC Manufacturing Fund Direct - Growth
0.00%
-2400000
-0.40%
-0.40%
HDFC Business Cycle Fund Direct - Growth
0.00%
-2038631
-1.37%
-1.32%
HDFC Pharma And Healthcare Fund Direct - Growth
0.00%
-1754783
-1.79%
-2.00%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
0.00%
-1579446
-0.62%
-0.63%
Tata Flexi Cap Fund Direct - Growth
0.00%
-1500000
-0.87%
-0.89%
Kotak Manufacture in India Fund Direct - Growth
0.00%
-1350000
-1.07%
0.00%
Invesco India Arbitrage Fund Direct-Growth
0.00%
-1227500
-0.10%
-0.02%
ICICI Prudential Business Cycle Fund Direct - Growth
0.00%
-1197222
-0.18%
-0.18%
Canara Robeco Multi Cap Fund Direct - Growth
0.00%
-1133946
-0.49%
-0.51%
ICICI Prudential Midcap Direct Plan-Growth
0.00%
-1091460
-0.32%
-0.33%
Franklin India Multi Cap Fund Direct-Growth
0.00%
-984055
-0.39%
-0.39%
ICICI Prudential Manufacturing Fund Direct - Growth
0.00%
-976877
-0.29%
-0.29%
LIC MF Manufacturing Fund Direct-Growth
0.00%
-928947
-2.12%
-0.97%
Kotak Balanced Advantage Fund Direct - Growth
0.00%
-875000
-0.10%
0.00%
Invesco India Manufacturing Fund Direct-Growth
0.00%
-874139
-2.15%
-2.17%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-785488
-0.62%
-0.62%
LIC MF Flexi Cap Fund Direct-Growth
0.00%
-714476
-1.38%
-1.42%

About Piramal Pharma

Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics (CHG) business, and an India Consumer Healthcare (ICH) business. Piramal Pharma Solutions provides integrated drug discovery, development, and manufacturing services. The company has a joint venture with Allergan in ophthalmology and a minority investment in Yapan Bio for biologics and vaccines. It is a leading player in India's self-care space with established brands. The company specializes in niche areas such as highly potent APIs, antibody drug conjugates, and biologics. In 2022, Piramal Pharma Limited was listed on the BSE and NSE following a demerger from Piramal Enterprises Limited.
Chairperson NameNandini Piramal